Binimetinib对比达卡巴嗪治疗晚期NRAS突变黑色素瘤(NEMO):一项多中心、开放标签、随机3期试验
NEMO研究在26国118家医院入组402例晚期NRAS突变黑色素瘤患者,按2:1随机接受binimetinib 45 mg每日两次口服或达卡巴嗪1000 mg/m2每3周静脉给药。中位随访1.7个月,binimetinib组中位无进展生存期2.8个月(95%CI 2.8-3.6)vs 达卡巴嗪组1.5个月(95%CI 1.5-1.7),HR 0.62(95%CI 0.47-0.80),单侧p<0.001。作者认为binimetinib可能成为免疫治疗失败后NRAS突变黑色素瘤的新选择。
要点
- binimetinib组中位无进展生存期2.8个月,达卡巴嗪组1.5个月,HR 0.62。
- 3-4级不良事件:肌酸磷酸激酶升高在binimetinib组52/269例(19%),达卡巴嗪组0/114例。
- 作者认为binimetinib可能成为免疫治疗失败后NRAS突变黑色素瘤的新治疗选择。
核心结论
- 与达卡巴嗪相比,binimetinib改善了无进展生存期且可耐受。
- 作者认为binimetinib可能成为免疫治疗失败后NRAS突变黑色素瘤患者的新治疗选择。
研究设计与样本
- NEMO是一项正在进行的多中心、开放标签、随机3期研究,在26个国家的118家医院开展。
- 入组标准为晚期不可切除、美国癌症联合委员会IIIC期或IV期NRAS突变黑色素瘤,既往未治疗或既往免疫治疗后进展。
- 按2:1随机分配至binimetinib 45 mg口服每日两次组(269例)或达卡巴嗪1000 mg/m2静脉每3周组(133例)。
- 随机分层因素为分期、体能状态和既往免疫治疗;主要终点为盲法中心评估的无进展生存期(意向治疗人群)。
- 安全性分析在安全性人群中进行,即至少接受一剂研究药物且有一次基线后安全性评估的所有患者。
主要发现
- 2013年8月19日至2015年4月28日共入组并随机402例患者,binimetinib组269例,达卡巴嗪组133例。
- 中位随访1.7个月(IQR 1.4-4.1)。
- 中位无进展生存期binimetinib组2.8个月(95%CI 2.8-3.6)vs 达卡巴嗪组1.5个月(95%CI 1.5-1.7),HR 0.62(95%CI 0.47-0.80),单侧p<0.001。
- 安全性人群中任一组至少5%患者发生的3-4级不良事件:肌酸磷酸激酶升高binimetinib组52/269例(19%)vs 达卡巴嗪组0/114例;高血压20/269例(7%)vs 2/114例(2%);贫血5/269例(2%)vs 6/114例(5%);中性粒细胞减少2/269例(1%)vs 10/114例(9%)。
- 严重不良事件(所有级别)binimetinib组91/269例(34%)vs 达卡巴嗪组25/133例(22%)。
关键数值与推荐
- binimetinib组中位无进展生存期2.8个月(95%CI 2.8-3.6),达卡巴嗪组1.5个月(95%CI 1.5-1.7)。
- HR 0.62(95%CI 0.47-0.80),单侧p<0.001。
- 3-4级肌酸磷酸激酶升高:binimetinib组52/269例(19%)vs 达卡巴嗪组0/114例。
- 3-4级高血压:binimetinib组20/269例(7%)vs 达卡巴嗪组2/114例(2%)。
- 3-4级中性粒细胞减少:binimetinib组2/269例(1%)vs 达卡巴嗪组10/114例(9%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are no established therapies specific for NRAS-mutant melanoma despite the emergence of immunotherapy. We aimed to assess the efficacy and safety of the MEK inhibitor binimetinib versus that of dacarbazine in patients with advanced NRAS-mutant melanoma. METHODS: NEMO is an ongoing, randomised, open-label phase 3 study done at 118 hospitals in 26 countries. Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma who were previously untreated or had progressed on or after previous immunotherapy were randomised (2:1) to receive either binimetinib 45 mg orally twice daily or dacarbazine 1000 mg/m2 intravenously every 3 weeks. Randomisation was stratified by stage, performance status, and previous immunotherapy. The primary endpoint was progression-free survival assessed by blinded central review in the intention-to-treat population. Safety analyses were done in the safety population, consisting of all patients who received at least one study drug dose and one post-baseline safety assessment. This study is registered with ClinicalTrials.gov, number NCT01763164 and with EudraCT, number 2012-003593-51. FINDINGS: Between Aug 19, 2013, and April 28, 2015, 402 patients were enrolled and randomly assigned, 269 to binimetinib and 133 to dacarbazine. Median follow-up was 1·7 months (IQR 1·4-4·1). Median progression-free survival was 2·8 months (95% CI 2·8-3·6) in the binimetinib group and 1·5 months (1·5-1·7) in the dacarbazine group (hazard ratio 0·62 [95% CI 0·47-0·80]; one-sided p<0·001). Grade 3-4 adverse events seen in at least 5% of patients the safety population in either group were increased creatine phosphokinase (52 [19%] of 269 patients in the binimetinib group vs none of 114 in the dacarbazine group), hypertension (20 [7%] vs two [2%]), anaemia (five [2%] vs six [5%]), and neutropenia (two [1%] vs ten [9%]). Serious adverse events (all grades) occurred in 91 (34%) patients in the binimetinib group and 25 (22%) patients in the dacarbazine group. INTERPRETATION: Binimetinib improved progression-free survival compared with dacarbazine and was tolerable. Binimetinib might represent a new treatment option for patients with NRAS-mutant melanoma after failure of immunotherapy. FUNDING: Array BioPharma and Novartis Pharmaceuticals Corporation.
引用
- Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017. PMID: 28284557. doi:10.1016/S1470-2045(17)30180-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。